In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk
The DOI matches its Crossref record.
Abstract
SOURCE CITATION: N Engl J Med. 2023;389:877-880. 37351564.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, the small-molecule orforglipron has not shown signals of pancreatitis, retinal detachment, or ischemic optic neuropathy.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [62]
In the citing paper
“In pooled analyses from T2D and obesity trials, treatment was associated with reductions in systolic and diastolic blood pressure, triglycerides, low-density lipoprotein cholesterol, and inflammatory markers, along with increases in high-density lipoprotein cholesterol [62].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [62]
Citations
Cites
Still being checked.
Cited by
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Zhao, W., Yin, Y., Shi, Z., Yang, K., Li, X., Yang, Y., Jing, T., & Kang, Z. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11213-7 · Cited by 1
Metadata
- Authors
- Lau, D.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Lau, Darren
- ORCID
- Lau, Darren
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2023-10
- Volume
- 176
- Issue
- 10
- Pages
- JC116
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4387246096
- Cited by
- 2
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- orlistat, weight loss, obesity, overweight, non-diabetic obesity, anti-obesity drugs, GLP-1 receptor agonists
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Gain, Weight Loss, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk. https://app.cochat.ai/papers/10.7326/j23-0077
- The paper
- Lau, D. (2023). In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk. Annals of Internal Medicine. https://doi.org/10.7326/j23-0077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.